KC-1073

Ba/F3-SLC34A2-ROS1-L2026M-Cell-Line

21485

Home » 细胞系 » Ba/F3-SLC34A2-ROS1-L2026M-Cell-Line

Background of Ba/F3-SLC34A2-ROS1-L2026M-Cell-Line

ROS1 is a receptor tyrosine kinase of the insulin receptor family, the overexpression of overactivity of ROS1 fusion proteins, due to chromosomal rearrangement, are associated with variety of cancers, including glioblastomas, Lung cancer. The identification of ROS1 fusion genes as driver genes have broaden the anticancer indication of variety of the inhibitors of other targets, such as Crizotinib, Alectinib, Ceritinib and Brigatinib, which can also inhibit the activation of ROS1. Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.

Specifications

Catalog Number	KC-1073
Cell Line Name	Ba/F3-SLC34A2-ROS1-L2026M-Cell-Line
Description	Stable Ba/F3 clone expressing exogenous SLC34A2-ROS1 fusion protein with L2026M amino acid mutation in ROS1 part.
Quantity	Two vials of frozen cells (≥2-10⁶/vial)
Stability	Stable in culture over a minimum of 10 passages
Application	Drug screening and biological assays
Freezing Medium	70% RPMI1640+20% FBS+10% DMSO
Propagation Medium	RPMI1640+10%FBS+1µg/mL Puromycin
Selection Marker	Puromycin
Morphology	Mostly single, round (some polymorph) cells in suspension
Subculture	Split saturated culture 1:10 every 3 days; seed out at about 1-3 × 10⁵ cells/mL
Incubation	37 °C with 5% CO₂
Storage	Liquid nitrogen immediately upon receiving
Doubling Time	Approximately 20 hours
Mycoplasma Status	Negative
In Vivo Validation	Yes

Cell Line Generation

Ba/F3 SLC34A2-ROS1-L2026M cell Line was generated using Lentiviral vector expressing human SLC34A2-ROS1- L2026M fusion sequence.

Characterization

Cell Resuscitation

Prewarm culture medium (RPMI1640 + 10% FBS + 1µg/mL Puromycin)in a 37°C water bath.
Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
Incubate the flask at 37°C, 5% CO₂ incubator.
Split saturated culture 1:10 every 3 days; seed out at about 1-3 × 10⁵ cells/mL.

Cell Freezing

Prepare the freezing medium (70% RPMI-1640 + 20% FBS + 10% DMSO) fresh immediately before use.
Keep the freezing medium on ice and label cryovials.
Transfer cells to a sterile, conical centrifuge tube, and count the cells.
Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
Resuspend the cells at a density of at least 3×10⁶ cells/mL in chilled freezing medium.
Aliquot 1 mL of the cell suspension into each cryovial.
Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
Transfer vials to liquid nitrogen for long-term storage

References

Gainor, J. F. & Shaw, A. T. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. The Oncologist 18, 865ÿ875 (2013)
Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863ÿ870 (2012).
Zou, H. Y. et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA 112, 3493ÿ3498 (2015).